DGIdb - IDARUBICIN Drug Record

IDARUBICIN chembl:CHEMBL1117 ApprovedAntineoplasticImmunotherapy

Alternate Names:

IDARUBICIN
IDAMYCIN
IMI-30
(1S,3S)-3-ACETYL-3,5,12-TRIHYDROXY-6,11-DIOXO-1,2,3,4,6,11-HEXAHYDRONAPHTHACEN-1-YL 3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSIDE
4-DEMETHOXYDAUNOMYCIN
4-DEMETHOXYDAUNORUBICIN
5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S-CIS)-
IDAMYCIN®
ZAVEDOS®
IDARUBICINA
IDARUBICINE
IDARUBICINUM
pubchem.compound:42890
chemidplus:58957-92-9
rxcui:5650
drugbank:01177
chembl:CHEMBL1117

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1990
FDA Approval	1990
Drug Class	small molecule
Drug Indications	Antineoplastic Agents

(5 More Sources)

Publications:

Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
LaRochelle et al., 2011, Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience., Oncotarget
Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
Zhou et al., 1999, Topoisomerase II-mediated alterations of K562 drug resistant sublines., Med. Oncol.
Willmore et al., 2002, Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells., Biochem. Pharmacol.
De Renzo et al., 1999, Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II., Am. J. Hematol.
Bigioni et al., 1994, Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage., Nucleic Acids Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
González-Cid et al., 2002, Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes., Toxicology
Megías-Vericat JE et al., 2018, Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy., Pharmacogenomics J
Reichwagen A et al., 2015, Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma., Pharmacogenomics
Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation
Serie DJ et al., 2017, Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial., Pharmacogenet Genomics
Hertz DL et al., 2016, Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines., Pharmacogenomics
Majsterek et al., 2003, TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin., Anticancer Drugs
Cheong HS et al., 2014, NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia., Pharmacogenet Genomics
Harousseau et al., 1996, Treatment of acute myeloblastic leukemia in adults. The GOELAM experience., Hematol Cell Ther

IDARUBICIN NCF4

Interaction Score: 5.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28763429 28485375 26799497 19448608 16330681

Sources:
PharmGKB
IDARUBICIN CYBA

Interaction Score: 2.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28485375 25823784 19448608 16330681

Sources:
PharmGKB
IDARUBICIN RAC2

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28485375

Sources:
PharmGKB
IDARUBICIN NT5C3A

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25000516

Sources:
PharmGKB
IDARUBICIN SULT2B1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
IDARUBICIN DNMT3A

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22081665

Sources:
CIViC
IDARUBICIN SLC22A12

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
IDARUBICIN DCK

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15564883

Sources:
PharmGKB
IDARUBICIN ETV6

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14501384

Sources:
NCI
IDARUBICIN TOP2A

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10523799 12034365 10203104 8036155 11752352 11836027

Sources:
TdgClinicalTrial TEND
IDARUBICIN CYP2E1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
IDARUBICIN CSF2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8915668

Sources:
NCI
IDARUBICIN SLCO1B1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
IDARUBICIN TOP2B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
IDARUBICIN ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB
IDARUBICIN FLT3

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
IDARUBICIN THRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN BLM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN MPHOSPH8

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN DRD1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN RECQL

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN POLH

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN APEX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN POLB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN HTT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN FEN1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN USP1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN POLI

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN POLK

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN ATAD5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN KCNH2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: IDARUBICIN
- Version: 01-August-2011
Alternate Names:

IDARUBICIN Primary Drug Name

Drug Info:

Year of Approval 1990

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: IDARUBICIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1990

Publications:

NCI: IDARUBICIN

Version: 14-September-2017

Alternate Names:

C562 NCI drug code

Drug Info:

Publications:

Majsterek et al., 2003, TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin., Anticancer Drugs

Harousseau et al., 1996, Treatment of acute myeloblastic leukemia in adults. The GOELAM experience., Hematol Cell Ther

PharmGKB: idarubicin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J

Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J

Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J

CIViC: IDARUBICIN
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

LaRochelle et al., 2011, Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience., Oncotarget
DTC: IDARUBICIN
- Version: 02-September-2020
Alternate Names:

CHEMBL1117 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Idarubicin
- Version: 2020.06.01
Alternate Names:

D01XDL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1117
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: IDARUBICINE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

IDARUBICIN Drug Record

IDARUBICIN chembl:CHEMBL1117 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28763429 28485375 26799497 19448608 16330681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28485375 25823784 19448608 16330681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28485375

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25000516

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22081665

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15564883

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14501384

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10523799 12034365 10203104 8036155 11752352 11836027

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8915668

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25567217 25558979 20938465 16331627

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
28763429 28485375 26799497 19448608 16330681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28485375 25823784 19448608 16330681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28485375

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25000516

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22081665

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15564883

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
14501384

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10523799 12034365 10203104 8036155 11752352 11836027

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8915668

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a